|
|
Pharmacy and Therapeutic (P&T) Committee and PDL
|
|
|
The Mississippi Division of Medicaid's Pharmacy and Therapeutics
(P&T) Committee is comprised
of twelve participating physicians, nurse practitioners, and practicing pharmacists
who are active MS Medicaid providers and in good standing with their representative
organizations. The P&T Committee is an advisory panel who conducts in-depth clinical evaluations and recommend
appropriate drugs for preferred status on DOM’s Preferred Drug List ( PDL ) and/or drugs for prior authorization.
Drugs and drug classes are evaluated for their safety,
efficacy, and overall cost value and the committee will make subsequent
recommendations to the Executive Director regarding prior authorization criteria
for these drugs and classes.
The decision of the committee regarding any limitations to be imposed on any drug
or its use for a specified indication shall be based on sound clinical evidence
found in labeling, drug compendia, and peer reviewed clinical literature pertaining
to use of the drug in the relevant population.
This Committee meets four times annually.
|
|
Preferred Drug List (PDL)
|
The preferred drug list is a medication list recommended to the Division of Medicaid
by the P& T Committee and approved by the Executive Director of the Division
of Medicaid. Drugs designated as preferred have been selected for their efficaciousness,
clinical significance, cost effectiveness and safety for Medicaid beneficiaries.
Most generic agents are preferred, do not require prior authorization, and may not
be individually listed. Unless otherwise specified, the listing of a particular
brand or generic name includes all dosage forms of that drug.
Medicaid-covered drugs noted as "non-preferred" will continue to be available through
the prior authorization process. A three-day emergency supply of prior-authorized
drugs can be dispensed by a pharmacy until authorization is completed.
The PDL only addresses certain drug classes. Drugs which have historically been
covered by Medicaid and are not listed on the Preferred Dug List will continue to
be covered. Some drug classes will not be reviewed for preferred status because
of no and/or limited cost savings, if the class is all and/or mostly generic, or
if there is low utilization in that class. Be advised that DOM may opt to include
or delete drug classes from PDL review in the future.
New drugs introduced into the marketplace in therapeutic classes that have been
reviewed will be considered non-preferred until the annual review of the particular
therapeutic class.
|
IMPORTANT INFORMATION FOR DRUG MANUFACTURERS |
|
Goold Health Systems, has been awarded the contract for Preferred Drug List Maintenance and Supplemental Rebate Program for the Mississippi Division of Medicaid (DOM) effective January 1, 2012. |
|
GHS |
**NOTICE** |
|
|
| Medicaid's Pharmacy & Therapeutics Committee Meeting Schedule: |
| March 13, 2012 |
| April 10, 2012 |
| September 11, 2012 |
| October 23, 2012 |
| The meetings will be held at 501 North West Street Conference Room 145 Jackson, MS 39201 |
| Meeting time is 10:00 a.m. - 5:00 p.m. |
Please route inquiries to phjpc@medicaid.state.ms.us or pharmacy bureau at 601-359-5253. |
|
|
Proposed Class Review Schedule for 2012 |
|
GHS SR team contact information
Goold Health Systems
PO Box 1090
Augusta, ME 04332-1090
Industry information requests
-
Industry representatives
with clinical inquires related to drugs listed on the Preferred Drug List may contact
the Division’s clinical contractor, Goold Health Systems (GHS). Chad Bissell, Pharm.
D. (cbissell@ghsinc.com)
is the primary contact at GHS for the Mississippi Medicaid Program.
|
Click Here to View Minutes for Previous Years' Pharmacy and Therapeutic Committee Meetings
|
Click Here to View Agendas for Previous Years' Pharmacy and Therapeutic Committee Meetings
|
|
|
|
Top
|